|
GB532822A
(en)
|
1939-08-11 |
1941-01-31 |
John David Kendall |
Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters
|
|
US4342691A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4342689A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4342690A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4299769A
(en)
|
1980-04-28 |
1981-11-10 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
EP0146243A1
(en)
|
1983-10-31 |
1985-06-26 |
Merck Frosst Canada Inc. |
Lipoxygenase inhibitors
|
|
EP0350990B1
(en)
|
1988-07-11 |
1995-09-20 |
Akzo Nobel N.V. |
Pyridazinone derivatives
|
|
ATE188379T1
(de)
|
1992-10-14 |
2000-01-15 |
Merck & Co Inc |
Fibrinogenrezeptor-antagonisten
|
|
US5569655A
(en)
|
1993-09-14 |
1996-10-29 |
Sterling Winthrop Inc. |
Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
|
|
JP2002517390A
(ja)
|
1998-06-03 |
2002-06-18 |
メルク エンド カムパニー インコーポレーテッド |
Ｈｉｖインテグラーゼ阻害薬
|
|
US6262055B1
(en)
|
1998-06-03 |
2001-07-17 |
Merck & Co., Inc. |
HIV integrase inhibitors
|
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
WO2001070675A2
(en)
|
2000-03-24 |
2001-09-27 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
|
US6448288B1
(en)
|
2000-05-17 |
2002-09-10 |
University Of Massachusetts |
Cannabinoid drugs
|
|
JP2004531238A
(ja)
|
2001-02-26 |
2004-10-14 |
ファーマ パシフィック プロプライエタリー リミテッド |
インターフェロン−アルファ誘導遺伝子
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
CN1845914A
(zh)
|
2003-09-02 |
2006-10-11 |
默克公司 |
用于治疗眼压过高的眼用组合物
|
|
WO2005089777A1
(en)
|
2004-03-15 |
2005-09-29 |
Karaolis David K R |
A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
AU2006304897B2
(en)
|
2005-10-18 |
2012-07-12 |
Janssen Pharmaceutica N.V. |
Method of inhibiting FLT3 kinase
|
|
EP1782826A1
(en)
|
2005-11-08 |
2007-05-09 |
GBF Gesellschaft für Biotechnologische Forschung mbH |
PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
|
|
KR101523391B1
(ko)
|
2006-12-27 |
2015-05-27 |
에모리 유니버시티 |
감염 및 종양 치료를 위한 조성물 및 방법
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
US8664255B2
(en)
|
2008-10-20 |
2014-03-04 |
The Texas A&M University System |
Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
WO2012068702A1
(zh)
|
2010-11-23 |
2012-05-31 |
中国医学科学院医药生物技术研究所 |
苯并五元不饱和杂环类化合物及其制备方法
|
|
JP5887947B2
(ja)
|
2011-03-28 |
2016-03-16 |
ソニー株式会社 |
透明導電膜、ヒータ、タッチパネル、太陽電池、有機ｅｌ装置、液晶装置および電子ペーパ
|
|
EP2697242B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
MX368257B
(es)
|
2011-08-01 |
2019-09-26 |
Genentech Inc |
Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
|
|
EP2858722B8
(en)
|
2012-06-08 |
2018-02-21 |
Aduro BioTech, Inc. |
Compostions and methods for cancer immunotherapy
|
|
US9695212B2
(en)
|
2012-12-13 |
2017-07-04 |
Aduro Biotech, Inc. |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
EP2934598B1
(en)
|
2012-12-19 |
2018-04-18 |
Board Of Regents, The University Of Texas System |
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
|
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
US9840533B2
(en)
|
2013-04-29 |
2017-12-12 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
WO2014179760A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
WO2014189806A1
(en)
|
2013-05-18 |
2014-11-27 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
|
|
PE20160080A1
(es)
|
2013-05-18 |
2016-02-21 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
|
|
US10176292B2
(en)
|
2013-07-31 |
2019-01-08 |
Memorial Sloan-Kettering Cancer Center |
STING crystals and modulators
|
|
JP2016538344A
(ja)
|
2013-11-19 |
2016-12-08 |
ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ |
癌処置としてのｓｔｉｎｇアゴニストの使用
|
|
WO2015074145A1
(en)
|
2013-11-22 |
2015-05-28 |
Brock University |
Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
|
|
US9315523B2
(en)
|
2013-12-06 |
2016-04-19 |
Rutgers, The State University Of New Jersey |
Cyclic dinucleosides
|
|
WO2015143712A1
(en)
|
2014-03-28 |
2015-10-01 |
Merck Sharp & Dohme Corp. |
4'-substituted nucleoside reverse transcriptase inhibitors
|
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
|
CN103908468B
(zh)
|
2014-04-21 |
2017-02-08 |
上海捌加壹医药科技有限公司 |
环二核苷酸cGAMP在制备抗肿瘤药物中的应用
|
|
CR20160564A
(es)
|
2014-06-04 |
2017-01-20 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos cíclicos como moduladores de sting
|
|
US20170121315A1
(en)
|
2014-06-12 |
2017-05-04 |
Bayer Pharma Aktiengesellschaft |
Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof
|
|
US10695426B2
(en)
*
|
2014-08-25 |
2020-06-30 |
Pfizer Inc. |
Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
|
|
WO2016096577A1
(en)
|
2014-12-16 |
2016-06-23 |
Invivogen |
Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
|
|
EP3546473B1
(en)
|
2014-12-16 |
2025-12-10 |
Kayla Therapeutics |
Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
|
|
US20180344758A1
(en)
|
2014-12-17 |
2018-12-06 |
Lipogen Llc |
Method of Treating Cancer with cGAMP or cGAsMP
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EA035817B1
(ru)
|
2015-03-10 |
2020-08-14 |
Адуро Байотек, Инк. |
Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
|
|
TW201717968A
(zh)
|
2015-07-14 |
2017-06-01 |
春季銀行製藥公司 |
誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
|
|
CA3030582A1
(en)
|
2015-07-22 |
2017-01-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Compounds and uses thereof in the treatment of cancers and other medical conditions
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
KR102222186B1
(ko)
|
2015-08-13 |
2021-03-03 |
머크 샤프 앤드 돔 코포레이션 |
Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
|
|
US9809597B2
(en)
|
2015-08-20 |
2017-11-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
|
|
JP2018534295A
(ja)
|
2015-10-28 |
2018-11-22 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
|
|
US20170146519A1
(en)
|
2015-11-20 |
2017-05-25 |
Oregon Health & Science University |
Sting agonists and methods of selecting sting agonists
|
|
CN107849084B
(zh)
|
2015-12-03 |
2021-09-14 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为sting调节剂的环状嘌呤二核苷酸
|
|
DE212016000029U1
(de)
|
2015-12-07 |
2017-07-30 |
Opi Vi - Ip Holdco Llc |
Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
|
|
ES2986067T3
(es)
*
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
KR102789862B1
(ko)
|
2016-01-11 |
2025-04-03 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
|
|
US10723756B2
(en)
|
2016-01-11 |
2020-07-28 |
Innate Tumor Immunity Inc. |
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
|
NZ746112A
(en)
|
2016-03-18 |
2023-01-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
JP2019510802A
(ja)
|
2016-04-07 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
タンパク質調節物質として有用な複素環アミド
|
|
PT3440076T
(pt)
|
2016-04-07 |
2022-07-29 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas úteis como modeladores de proteína
|
|
WO2017216726A1
(en)
|
2016-06-13 |
2017-12-21 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as inhibitors of dnmt1
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
PT3523287T
(pt)
*
|
2016-10-04 |
2021-10-06 |
Merck Sharp & Dohme |
Compostos de benzo[b]tiofeno como agonistas de sting
|